Prospective analysis of office-based hysteroscopic sterilization.
OBJECTIVE
To evaluate the efficacy of performing the Essure hysteroscopic sterilization in an office-based setting.


METHODS
Prospective, longitudinal analysis (Canadian Task Force classification II-3).


METHODS
University out-patient office.


METHODS
All patients undergoing permanent sterilization in our outpatient office who opted for hysteroscopic sterilization were included.


METHODS
Hysteroscopic placement of the Essure device in an office-based setting with only non-steroidal antiinflammatory drugs and paracervical block.


RESULTS
Multiple data points were collected on each patient including demographic data, specific procedural information, and 12-week hysterosalpingogram data. Most of our patients were Hispanic and had an average body mass index of 30.3. Average time to perform the procedure was 12.4 minutes, with the steepest improvement in the first 13 cases. Bilateral placement of the device was successful in 98 (96%) of 102 patients. Of these patients 92 have 12-week hysterosalpingography results (6 patients were lost to follow-up), with 90 (98%) showing bilateral tubal occlusion. There were no intraprocedural or postprocedural complications.


CONCLUSIONS
In our institution and in our experience, office-hysteroscopic placement of the Essure device is a feasible and effective approach for permanent sterilization.
Levie
Mark D
MD
Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA. malevie@montefiore.org
Chudnoff
Scott G
SG
D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D020702:Hysteroscopes; D015907:Hysteroscopy / Q000379:methods* / Q000706:statistics & numerical data; D015994:Incidence; D008137:Longitudinal Studies; D019060:Minimally Invasive Surgical Procedures / Q000379:methods / Q000706:statistics & numerical data; D009519:New York City; D010044:Outpatient Clinics, Hospital; D011446:Prospective Studies; D018570:Risk Assessment; D013245:Sterilization, Reproductive / Q000379:methods* / Q000706:statistics & numerical data; D016896:Treatment Outcome